To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Diacutaneous Fibrolysis in Patients with Mild-Moderate Carpal Tunnel Syndrome

Download
Share
Reprints
Cite This
About
+ Favorites
Download
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
October 2022

Diacutaneous Fibrolysis in Patients with Mild-Moderate Carpal Tunnel Syndrome

Vol: 298| Issue: 1| Number:3| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Diacutaneous Fibrolysis Intervention in Patients with Mild to Moderate Carpal Tunnel Syndrome May Avoid Severe Cases in Elderly: A Randomized Controlled Trial

Int J Environ Res Public Health. 2022 Sep 2;19(17):10983.

Contributing Authors:
S Jiménez-Del-Barrio L Ceballos-Laita E Bueno-Gracia S Rodríguez-Marco S Caudevilla-Polo E Estébanez-de-Miguel

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

Forty-four patients (60 wrists) with mild-moderate carpal tunnel syndrome were randomized to receive 5 sessions of diacutaneous fibrolysis treatment (n=20, 30 wrists) or a sham treatment (n=24, 30 wrists). The primary outcome of interest was the cross-sectional area of the median nerve. Secondary outcomes of interest included numbness on a Visual Analog Scale (VAS), the thickness of the transversa...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue